Sikiric P, Udovicic M, Barisic I, Balenovic D, Zivanovic Posilovic G, Strinic D, et al
Compound selection should be driven by demonstrated brain exposure rather than commercial prominence
Klein A, Schiffner R, Schiffner-Rohe J, Einsele-Kramer B, Heinlin J, Stolz W, Landthaler M
10.1172/JCI163669 134 PietrangeloT.FulleS.CosciaF.GigliottiP
Furthermore, advanced research into ferroptosis mechanisms in CHD may identify novel targets and strategies for CHD prevention and treatment, potentially mitigating myocardial injury by inhibiting ferroptosis-related signaling pathways or enhancing antioxidant capacity, ultimately improving cardiac function and quality of life for CHD patients
And the first GLP-1 for weight loss was approved in 2014, which suddenly seems like a long time ago